Evidence map›Paper›PMID 38884443›Full record

ArticleeLife2024

Structural characterization of ligand binding and pH-specific enzymatic activity of mouse Acidic Mammalian Chitinase.

Roberto Efraín Díaz, Andrew K Ecker, Galen J Correy, Pooja Asthana, Iris D Young, Bryan Faust, Michael C Thompson, Ian B Seiple, Steven Van Dyken, Richard M Locksley and 1 more

Abstract read
In one paragraph

Article in eLife, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Roberto Efraín DíazDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0000-0002-1172-9919
Andrew K EckerDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States.
Galen J CorreyDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, United States.
Pooja AsthanaDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, United States.
Iris D YoungDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, United States.
Bryan FaustDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States.
Michael C ThompsonChemistry and Chemical Biology Graduate Program, University of California, San Francisco, San Francisco, United States.
Ian B SeipleDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States.
Steven Van DykenDepartment of Pathology and Immunology, Washington University School of Medicine in St Louis, St Louis, United States.
Richard M LocksleyDepartment of Medicine, University of California, San Francisco, San Francisco, United States.
James S FraserDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0000-0002-5080-2859

Funding

X-ray Absorption Spectroscopy (XAS) pp.711-759P41GM103393 · NIGMS · STANFORD UNIVERSITY · PI HODGSON, KEITH O · 2012 to 2019
$30.6M
User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI Jay C. Nix · 2017 to 2026
$28.6M
Research Training in Chemistry and Chemical BiologyT32GM145460 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jason E Gestwicki · 2022 to 2026
$3.1M
Eliminating Critical Systematic Errors In Structural Biology With Next-Generation SimulationR01GM124149 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOLTON, JAMES M · 2017 to 2024
$2.5M
Targeting chitin in fibrotic lung diseaseR01HL148033 · NHLBI · WASHINGTON UNIVERSITY · PI VAN DYKEN, STEVEN · 2020 to 2023
$1.7M
Prevention and Public Health FundH23IP000554 · IP · CONNECTICUT STATE DEPT OF PUBLIC HEALTH · PI SACCO, VINCENT A · 2011 to 2011
$1.6M
National Science Foundation Graduate Research Fellowship Program 1650113NCIRD CDC HHS H23 IP000554NHLBI NIH HHS R01 HL148033NHLBI NIH HHS R01HL148033NIGMS NIH HHS P30 GM124169NIGMS NIH HHS P30GM124169NIGMS NIH HHS P41 GM103393NIGMS NIH HHS R01 GM124149NIGMS NIH HHS T32 GM145460University of California T29IP0554
6 · The paper itself

Abstract

Chitin is an abundant biopolymer and pathogen-associated molecular pattern that stimulates a host innate immune response. Mammals express chitin-binding and chitin-degrading proteins to remove chitin from the body. One of these proteins, Acidic Mammalian Chitinase (AMCase), is an enzyme known for its ability to function under acidic conditions in the stomach but is also active in tissues with more neutral pHs, such as the lung. Here, we used a combination of biochemical, structural, and computational modeling approaches to examine how the mouse homolog (mAMCase) can act in both acidic and neutral environments. We measured kinetic properties of mAMCase activity across a broad pH range, quantifying its unusual dual activity optima at pH 2 and 7. We also solved high-resolution crystal structures of mAMCase in complex with oligomeric GlcNAcn, the building block of chitin, where we identified extensive conformational ligand heterogeneity. Leveraging these data, we conducted molecular dynamics simulations that suggest how a key catalytic residue could be protonated via distinct mechanisms in each of the two environmental pH ranges. These results integrate structural, biochemical, and computational approaches to deliver a more complete understanding of the catalytic mechanism governing mAMCase activity at different pH. Engineering proteins with tunable pH optima may provide new opportunities to develop improved enzyme variants, including AMCase, for therapeutic purposes in chitin degradation.

Indexed as

ChitinChitinasesMolecular Dynamics SimulationAcetylglucosamineAnimalsCrystallography, X-RayHydrogen-Ion ConcentrationKineticsLigandsMiceModels, MolecularProtein BindingProtein ConformationAcetylglucosamineAMCase, mouseChitinChitinasesLigandsbiochemistrychemical biologychitinE. colienzymehumanlungmolecular biophysicsmousestructural biology

Identifiers

PMID38884443
PMCPMC11182645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.